Nasus Pharma Ltd. (NSRX)

Nasus Pharma Ltd. (NSRX) is a clinical-stage pharmaceutical company based in Israel that develops intranasal powder formulations of established medicines, with a focus on emergency treatments that can be administered quickly without a needle.

The company's lead program is a nasal powder form of epinephrine intended for the emergency treatment of severe allergic reactions, including anaphylaxis, designed as an alternative to auto-injectors. Nasus has also worked on intranasal powder versions of other emergency drugs, such as naloxone for opioid overdose, using its proprietary powder-based drug delivery technology that aims to support rapid absorption through the nasal tissue.

Nasus Pharma's ordinary shares are listed on NYSE American following its initial public offering in 2025.